JLK (CEO Dongmin Kim), a stroke AI specialized company, announced on the 17th that it has hired Professor Eunjeong Koh of Seoul National University Hospital, a neurosurgery and medical artificial intelligence (AI) expert, as an executive of the company.
With this recruitment, JLK will be able to further strengthen its research and clinical application of stroke AI solutions, and accelerate innovation in stroke workflow based on Professor Eun-Jeong Koh’s field clinical experience in neurosurgery.
Professor Eun-Jeong Koh (Director) received her medical degree from Seoul National University College of Medicine, and then earned her master’s degree in neurosurgery and her doctorate in translational medicine. She then served as a specialist at the Department of Neurosurgery and the Hospitalization Medicine Center at Seoul National University Hospital, accumulating abundant clinical experience and research achievements in the field of neurosurgery.
In particular, he has been conducting research on the discovery of multi-modal biomarkers such as body fluids, images, and biosignals, and the application of AI for the diagnosis and prognosis of neurological diseases including cerebrovascular diseases such as Moyamoya disease. His research excellence was recognized when he won the Neuro-Oncology Paper Award (Sim Bo-seong Academic Award) at the 2024 Fall Conference of the Korean Neurosurgical Society.
JLK CEO Dongmin Kim said, “Professor Eunjung Koh’s joining will be a significant turning point in realizing the stroke workflow innovation that JLK is pursuing,” and added, “We will do our best to actively utilize Professor Koh’s experience accumulated in the stroke treatment field to increase the precision of stroke AI solutions and advance AI technology with a clinical focus.”
Meanwhile, JLK recently succeeded in obtaining 510(k) approval from the U.S. Food and Drug Administration (FDA) for seven AI-based medical solutions (MEDIHUB Prostate, JBS-LVO, JLK-CTP, JLK-PWI, JLK-ICH, JLK-ailink, SDH). It also obtained approval from Japan’s PMDA for three solutions (JLK-CTP, JLK-PWI, NCCT AI solutions).
JLK is aiming to generate full-scale overseas sales this year by applying for additional overseas licenses and focusing on insurance acquisition activities. In the US, it is focusing on contracts with key hospitals to secure an initial supply chain, and in Japan, it is planning to accelerate the initial sales by indirectly selling through agencies.
- See more related articles
You must be logged in to post a comment.